Les premiers forages à Copper Rand ont retourné des intersections incluant 20,3 m à 4,2 g/t ÉqAu; de plus, le programme de forage initial à Gwillim a recoupé une minéralisation aurifère dans tous les trous
Les premiers forages à Copper Rand ont retourné des intersections incluant 20,3 m à 4,2 g/t ÉqAu; de plus, le programme de forage initial à Gwillim a recoupé une minéralisation aurifère dans tous les trous
Originally published via Source Article.
First drilling at Copper Rand has returned intersections including 20.3m at 4.2g/t AuEq; In addition, the maiden drill program at Gwillim has intersected gold mineralisation in all holes
First drilling at Copper Rand has returned intersections including 20.3m at 4.2g/t AuEq; In addition, the maiden drill program at Gwillim has intersected gold mineralisation in all holes
Originally published via Source Article.
Les premiers forages à Copper Rand ont retourné des intersections incluant 20,3 m à 4,2 g/t ÉqAu; de plus, le programme de forage initial à Gwillim a recoupé une minéralisation aurifère dans tous les trous
Les premiers forages à Copper Rand ont retourné des intersections incluant 20,3 m à 4,2 g/t ÉqAu; de plus, le programme de forage initial à Gwillim a recoupé une minéralisation aurifère dans tous les trous
Originally published via Source Article.
First drilling at Copper Rand has returned intersections including 20.3m at 4.2g/t AuEq; In addition, the maiden drill program at Gwillim has intersected gold mineralisation in all holes
First drilling at Copper Rand has returned intersections including 20.3m at 4.2g/t AuEq; In addition, the maiden drill program at Gwillim has intersected gold mineralisation in all holes
Originally published via Source Article.
Crown Point Announces Expiration of Concessions in Tierra Del Fuego
Originally published via Source Article.
CALGARY, Alberta, Aug. 27, 2026 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by Inventronics Limited (TSX Venture: IVX), please note that certain language was inadvertently carried forward from the Company’s Q1 2026 press release. The corrected release follows:
Originally published via Source Article.
Marking two decades of service with a 4.8-star rating across more than 2,000 Google reviews, the family-owned London plumber breaks down the basement flooding risks worth checking before the next heavy rain, and the City of London grant that covers up to 90 percent of the fix.
Marking two decades of service with a 4.8-star rating across more than 2,000 Google reviews, the family-owned London plumber breaks down the basement flooding risks worth checking before the next heavy rain, and the City of London grant that covers up to 90 percent of the fix.
Originally published via Source Article.
MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Project Orbis.
Originally published via Source Article.
MONTRÉAL, 27 août 2026 (GLOBE NEWSWIRE) — Thérapeutique Knight inc. (« Knight ») (TSX : GUD), société pharmaceutique panaméricaine (hors États-Unis), a annoncé aujourd’hui avoir déposé une demande supplémentaire auprès de l’ANVISA, l’agence brésilienne de réglementation de la santé, en vue d’obtenir l’autorisation d’une indication supplémentaire pour MINJUVI® (tafasitamab), en association avec le lénalidomide ajouté au R-CHOP (rituximab, cyclophosphamide, doxorubicine, vincristine et prednisone; Tafa-Len-R-CHOP), à titre de traitement de première intention chez les adultes atteints d’un lymphome diffus à grandes cellules B (DLBCL) ou d’un lymphome à cellules B de haut grade (HGBL) n’ayant reçu aucun traitement antérieur. La demande supplémentaire visant cette nouvelle indication a été sélectionnée pour un examen dans le cadre du Project Orbis.
Originally published via Source Article.
MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30 and August 14, 2026, the Company voluntarily applied for and the Company’s principal regulator, the British Columbia Securities Commission (the “BCSC”) granted a management cease trade order (the “MCTO”) dated July 30, 2026, under National Policy 12-203 Management Cease Trade Orders (“NP 12-203”) and provided the Company with an extension to file its annual financial statements for the year ended March 31, 2026, including the related management’s discussion and analysis, and Chief Executive Officer and Chief Financial certifications on or before July 29, 2026 (collectively the “Annual Financial Filings”). The deadline has been extended to on or before September 28, 2026.
Originally published via Source Article.
